AbbVie seeks EMA marketing authorisation for preventive migraine therapy
The MAA is based on data from two Phase III trials of atogepant in adult patients with episodic and chronic migraine.
A Program To Accelerate Sales
Biologic sales forecast to pass innovative small molecule sales in next five years
Roche reports 11% rise in group sales for Q1 2022
Ascletis seeks marketing authorisation for ritonavir in eight European countries
EC grants marketing authorisation for Pfizer-OPKO’s Ngenla injection
Molnupiravir Q4 forecast sales grow by 17,500% compared to Q3 forecast
EC grants marketing authorisation to GSK-Vir’s Xevudy for Covid-19
Acute glass bottle shortage threatens US spirits sales – leading macroeconomic influencers
